Liraglutide for weight loss: what the TikTok glow-ups skip over

What's this video probably claiming?

Based on the hashtags and caption framing, this is almost certainly a before-and-after weight loss transformation video crediting liraglutide, the GLP-1 receptor agonist sold as Saxenda for obesity and Victoza for type 2 diabetes. The creator tags #slowandsteady and #bodypositivity alongside #liraglutide, which suggests a personal journey narrative: gradual progress, emotional growth, and medication as a supportive tool rather than a magic fix. That framing is refreshingly honest compared to a lot of GLP-1 content. But transformation videos, even well-intentioned ones, tend to compress months of clinical complexity into a 60-second clip. They show the results. They rarely show the 3 a.m. nausea, the plateaus, the insurance fights, or the data on what happens when people stop. So while the sentiment here seems genuine, the implicit claims still deserve scrutiny.

What does the science actually show?

Liraglutide at 3.0 mg daily (the Saxenda dose, not the lower Victoza dose) produces meaningful but modest weight loss compared to newer agents. The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found participants lost an average of 8.4 kg over 56 weeks versus 2.8 kg on placebo. That is about 5-6% of body weight on average, though roughly a third of participants hit 10% or more. For comparison, semaglutide 2.4 mg weekly produced about 14.9% body weight reduction in the STEP 1 trial (Wilding et al., 2021, NEJM). Liraglutide requires daily injections versus weekly for semaglutide, and its cost-to-efficacy ratio has led many clinicians to transition patients to semaglutide or tirzepatide when those options are accessible. The drug does work. The numbers just matter when social media implies all GLP-1s are equivalent.

Where does the social media noise diverge from clinical reality?

Transformation videos create a survivorship bias problem. You see the people for whom liraglutide delivered visible results. You do not see the roughly 30% of SCALE trial participants who did not achieve even 5% body weight loss. You also rarely see discussion of weight regain. A 2022 follow-up analysis published in Diabetes, Obesity and Metabolism (Rubino et al.) showed that patients who stopped semaglutide regained about two-thirds of lost weight within a year, and the liraglutide discontinuation data tells a similar story. GLP-1 therapy for obesity is, for most people, a long-term or indefinite commitment, not a course you complete. Side effect profiles are also glossed over. Gastrointestinal adverse events caused roughly 10% of liraglutide participants in SCALE to discontinue treatment. That is not rare. Pancreatitis risk, while debated in magnitude, carries an FDA label warning that deserves mention.

What should you actually know?

Liraglutide is a legitimate, FDA-approved tool for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related comorbidity. It works by mimicking GLP-1, slowing gastric emptying and reducing appetite. But it is also the oldest and, by efficacy data, the least potent of the currently available injectable GLP-1 options for weight loss. Patients and prescribers are increasingly choosing semaglutide or tirzepatide when access allows. If you are seeing a creator's liraglutide results and wondering whether to ask your doctor, that conversation is worth having. What is not worth having is the assumption that results will mirror what you see in a 27,000-view TikTok. Individual response varies substantially, duration of therapy matters, and access to any of these medications through a regulated telehealth platform means getting a proper clinical evaluation, not just a prescription triggered by a before-and-after video.